An observational study in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 30 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Hoffmann-La Roche · Observational
A Prospective, Multicenter, Non-Interventional Study of Primary Data Collection, Designed to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcomes in Patients with Breast Cancer in Latin America.
14,825 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
This study's enrollment of 2,907 is above the median of 184 across 3,235 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Hoffmann-La Roche is the lead sponsor of 2,101 studies on the registry; 87 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
The patients will be recruited from approximately 10 countries and from a variety of healthcare sites (ex: specialty care, private practice, teaching institution, etc.)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Drug: Bevacizumab
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Drug: Trastuzumab
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Drug: Ado-trastuzumab emtamsine
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Drug: Pertuzumab
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Drug: Atezolizumab
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Drug: Capecitabine
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Also known as: Avastin
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Also known as: Herceptin
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Also known as: Kadcyla
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Also known as: Perjeta
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Also known as: Tecentriq
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Percentage of Participants with Different Breast Cancer Subtypes at Diagnosis in Latin America
Time frame: Baseline up to 12 months
Percentage of Participants with Pathological Complete Response (pCR defined ypT0/is, N0)
Time frame: Baseline up to approximately 6 years
Percentage of Participants with Locoregional Recurrence (LRR)
Time frame: Baseline up to approximately 6 years
Percentage of Participants with Event Free Survival (EFS)
Time frame: Baseline up to approximately 6 years
Percentage of Participants with Invasive Disease-Free Survival (iDFS)
Time frame: Baseline up to approximately 6 years
Percentage of Participants with Overall Survival
Time frame: Baseline up to approximately 6 years
Percentage of Participants with Objective Response Rate (ORR)
Time frame: Baseline up to approximately 6 years
Percentage of Participants with Anti-Cancer Treatment Modifications
Time frame: Baseline up to approximately 6 years
Percentage of Participants with Breast Cancer Treatment based on Different Socio-Demographics Characteristics
Time frame: Baseline up to approximately 6 years
Percentage of Participants (During Observation Period) with Pregnancy
Time frame: Baseline up to approximately 6 years
Percentage of Participants (during Observation Period) with Pregnancy Outcomes
Time frame: Baseline up to approximately 6 years
Percentage of Participants with Non-Serious Adverse Events of Special Interests
Time frame: Baseline up to approximately 6 years
Percentage of Participants with AEs Leading to Discontinuation or Dose Modification
Time frame: Baseline up to approximately 6 years
Percentage of Participants with Cardiac Safety Events
Time frame: Baseline up to approximately 6 years
Percentage of Participants Adherent to Predefined Clinical Guideliens Regarding Anti-Cancer Treatment Regimens
Time frame: Baseline up to approximately 6 years
Percentage of Partcipants with Access to Biomarker Testing and Diagnostic Methods
Time frame: Baseline up to approximately 6 years
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.